A new test developed by researchers at The Pirbright Institute, in collaboration with the University of Queensland and the University of Oxford, can detect antibodies that prevent cell-to-cell fusion, a method some viruses use to infect neighbouring cells.
The Pirbright Institute will undertake two projects with ECO Animal Health Group plc (ECO) to develop vaccine candidates for porcine respiratory and reproductive syndrome virus (PRRSV). The first project is a tripartite collaboration between The Pirbright Institute, The Vaccine Group (TVG) and ECO whilst the second project is a joint collaboration between Pirbright and ECO.
Studies undertaken at The Pirbright Institute in collaboration with Inovio Pharmaceuticals have shown that a human antibody (2-12C) can provide pigs protection against the 2009 H1N1 pandemic strain of human influenza. This finding indicates that the antibody could also be effective at treating human influenza infections and demonstrates that the pig is an excellent model for assessing antibody therapies.
Studies at Pirbright demonstrate two doses of Oxford University’s COVID-19 vaccine boosts immune response in pigs
The Pirbright Institute, working in collaboration with the University of Oxford have successfully shown that two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine produce a greater antibody response than a single dose in pigs.
Scientists at The Pirbright Institute have shown that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for coronavirus disease (COVID-19), is able to enter cells using the receptors of multiple mammalian species. The broad host range of SARS-CoV-2 confirms the potential risk of infection to a wide range of companion animals, livestock and wildlife.
Scientists from The Pirbright Institute are a step closer to developing a vital vaccine for African swine fever (ASF), a pig disease that the World Organisation for Animal Health (OIE) has warned could kill a quarter of the world’s pigs, partly due to the absence of a commercially available vaccine. Their study, published in Vaccines showed that 100 percent of pigs immunised with the new vaccine were protected from a lethal dose of ASF virus (ASFV).
Scientists in the Non-Vesicular Reference Laboratory (NVRL) at The Pirbright Institute have confirmed an outbreak of African horse sickness (AHS) in Thailand. AHS is the most lethal viral disease of horses known and the rapid diagnostic services provided by Pirbright has enabled authorities to respond quickly to the outbreak, the first that south-east Asia has ever experienced.
Scientists from The Pirbright Institute have worked with UCL to map the expression of genes across the entire African swine fever virus (ASFV) genome, which has helped to establish their order of activation as well as uncovering new genes. The research could provide vital information for those developing vaccines and antiviral drugs to prevent the deadly pig disease caused by this virus.
New strategic bioimaging collaboration announced between The Pirbright Institute and Diamond Light Source
A new five-year collaboration agreement is now in place between The Pirbright Institute and Diamond Light Source, which aims to enable scientists to study viral diseases in greater detail.
Bill & Melinda Gates Foundation funds development of Pirbright’s Livestock Antibody Hub supporting animal and human health
Researchers from The Pirbright Institute have been awarded US $5.5 million by the Bill & Melinda Gates Foundation to establish a Livestock Antibody Hub aimed at improving animal and human health globally. The ambitious programme of work will see extensive collaboration between multiple UK research organisations in order to utilise research outcomes in livestock disease and immunology to support human health as part of the ‘One Health’ agenda.